RxDoctor Payments Data

Sean Considine, MD

Ophthalmology · Wilmington, DENPI 1861029068

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.3% of the total across 70 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 18.2% — the pattern of someone who eats at a lot of different presentations.

$2,083in general payments, 2019–2025

Across 70 payments — averaging $29.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$380
  • Mallinckrodt Hospital Products Inc.$309
  • AbbVie$255
  • Biotissue Holdings Inc.$224
  • Tarsus Pharmaceuticals, Inc.$171
  • Bausch & Lomb Americas Inc.$156
  • plus $588 from 11 others

What the payments were for

  • Food & beverage$1,98595%
  • Education$985%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,083 in reported general payments places this provider in the 75th percentile of 49 ophthalmology providers in Delaware.

See all ophthalmology providers in Delaware

Medicare billing

Part B allowed, 2024
$46,169
Medicare patients
217
Services billed
509

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate49$2,171
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat30$848
Latanoprost73$719
Atropine Sulfate16$491
Ketorolac Tromethamine15$301
Brimonidine Tartrate21$193
Diclofenac Sodium19$142

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Wilmington

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →